- Home
- TCRX
as of 03-10-2026 3:44pm EST
$1.18
$0.02
-1.41%
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 63.6M | IPO Year: | 2021 |
| Target Price: | $8.00 | AVG Volume (30 days): | 465.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.00 | EPS Growth: | 12.28 |
| 52 Week Low/High: | $0.88 - $2.57 | Next Earning Date: | N/A |
| Revenue: | $10,325,000 | Revenue Growth: | 266.65% |
| Revenue Growth (this year): | -22.2% | Revenue Growth (next year): | 69.75% |
| P/E Ratio: | -1.12 | Index: | N/A |
| Free Cash Flow: | -139726000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of TScan Therapeutics Inc. (TCRX)
Lynx1 Capital Management LP
Buy
10% Owner
TCRX Dec 23, 2025
Avg Cost/Share
$0.90
Shares
6,232
Total Value
$5,601.94
Owned After
8,019,148
SEC Form 4
Lynx1 Capital Management LP
Buy
10% Owner
TCRX Dec 22, 2025
Avg Cost/Share
$0.90
Shares
75,500
Total Value
$67,950.00
Owned After
8,019,148
SEC Form 4
Lynx1 Capital Management LP
Buy
10% Owner
TCRX Dec 19, 2025
Avg Cost/Share
$0.90
Shares
80,069
Total Value
$71,974.02
Owned After
8,019,148
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | TCRX | 10% Owner | Dec 23, 2025 | Buy | $0.90 | 6,232 | $5,601.94 | 8,019,148 | |
| Lynx1 Capital Management LP | TCRX | 10% Owner | Dec 22, 2025 | Buy | $0.90 | 75,500 | $67,950.00 | 8,019,148 | |
| Lynx1 Capital Management LP | TCRX | 10% Owner | Dec 19, 2025 | Buy | $0.90 | 80,069 | $71,974.02 | 8,019,148 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 12, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 12, 2025 · 100% conf.
AI Prediction SELL
1D
-0.47%
$1.18
5D
-12.87%
$1.04
20D
-17.82%
$0.98
Price: $1.19 Prob +5D: 0% AUC: 1.000
0001193125-25-275889
8-K
0001783328false00017833282025-11-122025-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
November 12, 2025
TSCAN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-40603
82-5282075
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
830 Winter Street
Waltham, Massachusetts
02451
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code
857 399-9500
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Voting Common Stock, par value $0.0001 per share
TCRX
The Nasdaq Global Market, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 12, 2025, TScan Therapeutics, Inc. issued a press release announcing its financial results for the third quarter September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
Exhibit No.
Description
99.1
Press Release issued by TScan Therapeutics, Inc., dated November 12, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TScan Therapeutics, Inc.
Date:
November 12, 2025
By:
/s/ Gavin MacBeath
Gavin MacBeath, Ph.D Chief Executive Officer (Principal Executive Officer)
2025 Q2 Q2 2025 Earnings
8-K Aug 12, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 12, 2025
0000950170-25-106915
8-K
false000178332800017833282025-08-122025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
August 12, 2025
TSCAN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-40603
82-5282075
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
830 Winter Street
Waltham, Massachusetts
02451
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code
857 399-9500
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Voting Common Stock, par value $0.0001 per share
TCRX
The Nasdaq Global Market, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 12, 2025, TScan Therapeutics, Inc. issued a press release announcing its financial results for the second quarter June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
Exhibit No.
Description
99.1
Press Release issued by TScan Therapeutics, Inc., dated August 12, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TScan Therapeutics, Inc.
Date:
August 12, 2025
By:
/s/ Gavin MacBeath
Gavin MacBeath, Ph.D Chief Executive Officer (Principal Executive Officer)
2025 Q1 Q1 2025 Earnings
8-K May 6, 2025
2025
Q1
Q1 2025 Earnings
8-KMay 6, 2025
0000950170-25-063959
8-K
false000178332800017833282025-05-062025-05-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 6, 2025
TSCAN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-40603
82-5282075
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
830 Winter Street
Waltham, Massachusetts
02451
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code
857 399-9500
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Voting Common Stock, par value $0.0001 per share
TCRX
The Nasdaq Global Market, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On May 6, 2025, TScan Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
Exhibit No.
Description
99.1
Press Release issued by TScan Therapeutics, Inc., dated May 6, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TScan Therapeutics, Inc.
Date:
March 6, 2025
By:
/s/ Gavin MacBeath
Gavin MacBeath, Ph.D Chief Executive Officer (Principal Executive Officer)
Latest TScan Therapeutics Inc. News
TCRX Breaking Stock News: Dive into TCRX Ticker-Specific Updates for Smart Investing
Compare TCRX vs Leading Stocks
See how TCRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TCRX TScan Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.